Key Details
Last Dividend
$1.51Annual ROE
-41.04%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 10, 2023Recent annual earnings:
Mar 17, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
Oct 20, 2023Next split:
N/ARecent split:
Oct 20, 2023Analyst ratings
Recent major analysts updates
17 Apr '23 HC Wainwright & Co.
Neutral23 Feb '23 Morgan Stanley
Equal-Weight30 Jan '23 HC Wainwright & Co.
Buy24 Oct '22 HC Wainwright & Co.
Buy20 Oct '22 SVB Leerink
Market Perform20 Oct '22 HC Wainwright & Co.
Buy09 Sept '22 Morgan Stanley
Equal-Weight05 July '22 Morgan Stanley
Equal-Weight01 July '22 SVB Leerink
Market Perform24 May '22 Morgan Stanley
OverweightScreeners with TALS included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Talaris Therapeutics?
- What is the ticker symbol for Talaris Therapeutics?
- Does Talaris Therapeutics pay dividends?
- What sector is Talaris Therapeutics in?
- What industry is Talaris Therapeutics in?
- What country is Talaris Therapeutics based in?
- When did Talaris Therapeutics go public?
- Is Talaris Therapeutics in the S&P 500?
- Is Talaris Therapeutics in the NASDAQ 100?
- Is Talaris Therapeutics in the Dow Jones?
- When was Talaris Therapeutics's last earnings report?
- When does Talaris Therapeutics report earnings?
- Should I buy Talaris Therapeutics stock now?
What is the primary business of Talaris Therapeutics?
As of October 19, 2023, Talaris Therapeutics, Inc. was acquired by Tourmaline Bio, Inc., in a reverse merger transaction. Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.
What is the ticker symbol for Talaris Therapeutics?
The ticker symbol for Talaris Therapeutics is NASDAQ:TALS
Does Talaris Therapeutics pay dividends?
No, Talaris Therapeutics does not pay dividends
What sector is Talaris Therapeutics in?
Talaris Therapeutics is in the Healthcare sector
What industry is Talaris Therapeutics in?
Talaris Therapeutics is in the Biotechnology industry
What country is Talaris Therapeutics based in?
Talaris Therapeutics is headquartered in United States
When did Talaris Therapeutics go public?
Talaris Therapeutics's initial public offering (IPO) was on 07 May 2021
Is Talaris Therapeutics in the S&P 500?
No, Talaris Therapeutics is not included in the S&P 500 index
Is Talaris Therapeutics in the NASDAQ 100?
No, Talaris Therapeutics is not included in the NASDAQ 100 index
Is Talaris Therapeutics in the Dow Jones?
No, Talaris Therapeutics is not included in the Dow Jones index
When was Talaris Therapeutics's last earnings report?
Talaris Therapeutics's most recent earnings report was on 10 November 2023
When does Talaris Therapeutics report earnings?
The date for Talaris Therapeutics's next earnings report has not been announced yet
Should I buy Talaris Therapeutics stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions